Edmond de Rothschild Investment Partners co-leads the ?12 Million Series B financing of Complix with its new fund BioDiscovery 4
(Thomson Reuters ONE) -
Edmond de Rothschild Investment Partners /
Edmond de Rothschild Investment Partners co-leads the ?12 Million Series B
financing of Complix with its new fund BioDiscovery 4
. Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Paris, France - Edmond de Rothschild Investment Partners announces the second
investment of BioDiscovery 4, its fourth fund dedicated to Life Sciences,
through its participation in the Series B financing round of Complix, which it
co-leads with GIMV.
Complix, formed in 2008, was founded in Hasselt, Belgium. Edmond de Rothschild
Investment Partners led alongside GIMV the Series B round financing of ?12
million which will be invested in developing a first set of therapeutic
Alphabodies(TM) to treat cancer and autoimmune indications and to further
develop and validate the Company's unique Alphabody platform.
Complix is developing Alphabodies, a transformative biotherapeutic platform with
the ability to modulate the intracellular protein-to-protein interactions
(PPIs), which play a key role in the initiation and progression of many
important diseases. As such, these Alphabodies have the capacity to address a
vast number of disease targets that are currently considered "undruggable" by
the two main classes of therapeutic drugs, small chemical drugs and therapeutic
proteins, and represent a major medical and commercial opportunity for Complix
and its partners.
Gilles Nobecourt, Partner at Edmond de Rothschild Investment Partners, who will
join the Board Director at Complix, commented: "We were attracted by
Alphabodies' unique ability to modulate intracellular protein-protein
interactions which offers an unprecedented opportunity to create a new class of
proprietary and truly differentiated products. We were impressed by the team at
Complix, which has created this new scaffold and demonstrated in-vitro its
potential to address intractable intra cellular targets. Based on this initial
success we believe there is a strong basis for building a successful company".
Mark Vaeck, Co-Founder and CEO of Complix added: "We look forward to working
with our new investors Edmond de Rothschild Investment Partners and GIMV to
ensure the expeditious implementation of our ambitious plans and vision. We are
confident that our Alphabody platform can deliver the next generation drugs that
the pharmaceutical industry is eagerly looking for to drive its growth and
tackle a broad range of diseases where treatment options are limited or non-
existent."
About Edmond de Rothschild Investment Partners
Paris-based Edmond de Rothschild Investment Partners is dedicated to minority
investments into privately-owned companies. It currently has close to ?1 billion
under management which is being invested primarily as life sciences venture
capital and growth capital.
Its Life Sciences Team of eight professionals brings together over 60 years of
experience in the Life Science industry and more than 100 years of private
equity and venture capital experience. The team has ?355 million under
management through its Biodiscovery franchise.
BioDiscovery Funds, including BioDiscovery 4, are venture capital funds
registered via the fast-track procedure. These funds are not authorized by the
Autorité des Marchés Financiers and may adopt special investment rules.
BioDiscovery 4, a Capital Venture Funds registered via the fast-track procedure,
invests mainly in private companies, which involves specific risks such as a
risk of capital loss, a discretionary management risk and a liquidity risk.
Edmond de Rothschild Investment Partners is the private equity affiliate of the
Edmond de Rothschild Group, which is specialised in asset management and private
banking (EUR 130bn under management, 2,900 employees and 30 offices throughout
the world). Founded in 1953, the Group has been chaired since 1997 by Baron
Benjamin de Rothschild.
About Complix
Complix is a biopharmaceutical company developing a pipeline of transformative
protein therapeutics, called Alphabodies(TM), mainly focused on oncology and
autoimmune diseases.
Alphabodies are a revolutionary class of protein therapeutics that have the
potential to address a wide range of disease targets, in particular
intracellular targets that are considered undruggable by current drug formats,
such as antibodies or small chemicals. Complix` current R&D efforts are mainly
focused on the development of Cell-Penetrating Alphabodies (CPABs) that have the
unique capacity to enter tumor cells effectively and selectively modulate
intracellular protein-to-protein interactions (PPIs) which play a key role in
the initiation and progression of cancer.
Complix has established a strong intellectual property position protecting the
Alphabody(TM) platform and its emerging product portfolio through the filing of
multiple broad patent applications. Alphabody-based therapeutics are independent
of antibody-based patent claims and offer a unique freedom-to-operate position.
Since its founding in 2008 Complix has raised a total of ?26 million in funding
(approximately US$ 34 million), including a ?12 million B round in June 2013 and
a ?7 million Series A equity round in 2010.
Complix is headquartered in Hasselt (Belgium) in the Life Sciences incubator
BioVille, and has research facilities in Ghent (Belgium) and Luxembourg. The
Company has a fully owned subsidiary in Luxembourg and has established research
alliances with CRP-Santé (Luxembourg) and VIB (Belgium).
For more information, please visit www.complix.com.
Contacts
Edmond de Rothschild Investment Partners
Gilles Nobecourt
Gilles.NOBECOURT(at)lcfr.fr
Tel: +33 1 40 17 27 69
Complix NV
Dr. Mark Vaeck, CEO
Mark.Vaeck(at)Complix.com
Tel: +32 9 261 69 40
Press Release PDF:
http://hugin.info/139296/R/1712048/568090.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Edmond de Rothschild Investment Partners via Thomson Reuters ONE
[HUG#1712048]
Unternehmensinformation / Kurzprofil:
Datum: 26.06.2013 - 10:03 Uhr
Sprache: Deutsch
News-ID 273301
Anzahl Zeichen: 7374
contact information:
Town:
Paris
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 222 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Edmond de Rothschild Investment Partners co-leads the ?12 Million Series B financing of Complix with its new fund BioDiscovery 4"
steht unter der journalistisch-redaktionellen Verantwortung von
Edmond de Rothschild Investment Partners (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
